Side effects among healthcare workers from a large Milan university hospital after second dose of BNT162b2 mRNA COVID-19 vaccine.
Journal
La Medicina del lavoro
ISSN: 0025-7818
Titre abrégé: Med Lav
Pays: Italy
ID NLM: 0401176
Informations de publication
Date de publication:
23 Dec 2021
23 Dec 2021
Historique:
received:
04
11
2021
accepted:
01
12
2021
entrez:
23
12
2021
pubmed:
24
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
In Italy, healthcare workers (HCWs) were among the first to receive COVID-19 vaccination. Aim of the present study is to evaluate frequency and severity of adverse events (AEs) following the second dose of BNT162b2 vaccine among HCWs of a large university hospital in Milan, Italy. One month after having received the second dose of vaccine, HCWs filled-in a form about type, severity, and duration of post-vaccination local and systemic symptoms. We calculated the overall frequency of AEs and used multivariable Poisson regression models (adjusted for sex, age, BMI, smoking, allergy history, previous SARS-CoV-2 infection, anti-hypertensive therapy, and occupation) to calculate risk ratios (RR) and 95% confidence intervals (CI) of AEs according to selected variables. We included 3659 HCWs. Overall, 2801 (76.6%) experienced at least one local event, with pain at injection site being the most frequent (2788, 76.2%). Systemic events were reported by 2080 (56.8%) HCWs, with fatigue (52.3%), muscle pain (42.2%), headache (37.7%), joint pain (31.9%), and fever (26.2%) being the most frequent. Risks of systemic events were associated with female gender (RR=1.14, CI: 1.06-1.23), age (strong decrease with increasing age, p-trend<0.001), allergy history (RR=1.13, CI: 1.05-1.20), and current smoking (RR=0.90, CI: 0.84-0.97). HCWs with previous SARS-CoV-2 infection (even if symptomatic) were not at increased risk. Both local and systemic acute effects after second dose of BNT162b2 vaccine were frequently reported. However, symptoms were mostly light/mild and of short duration. Thus, our findings support the safety of COVID-19 vaccination in adults in relatively good health.
Sections du résumé
BACKGROUND
BACKGROUND
In Italy, healthcare workers (HCWs) were among the first to receive COVID-19 vaccination. Aim of the present study is to evaluate frequency and severity of adverse events (AEs) following the second dose of BNT162b2 vaccine among HCWs of a large university hospital in Milan, Italy.
METHODS
METHODS
One month after having received the second dose of vaccine, HCWs filled-in a form about type, severity, and duration of post-vaccination local and systemic symptoms. We calculated the overall frequency of AEs and used multivariable Poisson regression models (adjusted for sex, age, BMI, smoking, allergy history, previous SARS-CoV-2 infection, anti-hypertensive therapy, and occupation) to calculate risk ratios (RR) and 95% confidence intervals (CI) of AEs according to selected variables.
RESULTS
RESULTS
We included 3659 HCWs. Overall, 2801 (76.6%) experienced at least one local event, with pain at injection site being the most frequent (2788, 76.2%). Systemic events were reported by 2080 (56.8%) HCWs, with fatigue (52.3%), muscle pain (42.2%), headache (37.7%), joint pain (31.9%), and fever (26.2%) being the most frequent. Risks of systemic events were associated with female gender (RR=1.14, CI: 1.06-1.23), age (strong decrease with increasing age, p-trend<0.001), allergy history (RR=1.13, CI: 1.05-1.20), and current smoking (RR=0.90, CI: 0.84-0.97). HCWs with previous SARS-CoV-2 infection (even if symptomatic) were not at increased risk.
CONCLUSIONS
CONCLUSIONS
Both local and systemic acute effects after second dose of BNT162b2 vaccine were frequently reported. However, symptoms were mostly light/mild and of short duration. Thus, our findings support the safety of COVID-19 vaccination in adults in relatively good health.
Identifiants
pubmed: 34939617
doi: 10.23749/mdl.v112i6.12507
pmc: PMC8759050
doi:
Substances chimiques
COVID-19 Vaccines
0
RNA, Messenger
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
477-485Références
Vaccines (Basel). 2021 Sep 11;9(9):
pubmed: 34579248
MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):283-288
pubmed: 33630816
Lancet. 2021 Mar 20;397(10279):1057-1058
pubmed: 33640038
JAMA. 2021 Jun 1;325(21):2201-2202
pubmed: 33818592
Vaccines (Basel). 2020 Dec 06;8(4):
pubmed: 33291245
Mech Ageing Dev. 2005 Aug;126(8):874-81
pubmed: 15876450
BMJ. 2021 Feb 2;372:n308
pubmed: 33531333
J Clin Invest. 2017 Jan 3;127(1):65-73
pubmed: 28045405
Nat Rev Immunol. 2002 May;2(5):372-7
pubmed: 12033743
NPJ Vaccines. 2019 Sep 24;4:39
pubmed: 31583123
J Infect. 2021 Sep;83(3):381-412
pubmed: 34062184
Cell Immunol. 2015 Apr;294(2):87-94
pubmed: 25708485
Oncotarget. 2017 Jan 3;8(1):268-284
pubmed: 27902485
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
Int J Infect Dis. 2021 May;106:376-381
pubmed: 33866000
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Lancet Infect Dis. 2010 May;10(5):338-49
pubmed: 20417416
EClinicalMedicine. 2021 Jun;36:100914
pubmed: 34095793
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
Cell Immunol. 2015 Apr;294(2):63-9
pubmed: 25682174
J Microbiol Biotechnol. 2020 Aug 28;30(8):1109-1115
pubmed: 32627758
J Community Health. 2021 Oct 9;:
pubmed: 34628568
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Infect Public Health. 2021 Aug;14(8):1120-1122
pubmed: 34293641